SCHEMBL10001153

SCHEMBL10001153

CC(C)(C)C(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
RECQL P46063 1/20 0.55
CA2 P00918 3/20 0.54
CA1 P00915 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 3/20 0.52
POLB P06746 1/20 0.52
TYR P14679 1/20 0.52
NPSR1 Q6W5P4 2/20 0.52
ALOX5 P09917 2/20 0.51
PTGS1 P23219 2/20 0.51
PTGS2 P35354 2/20 0.51
GAA P10253 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
GLRA3 O75311 1/20 0.50
GLRB P48167 1/20 0.50
TNFRSF1A P19438 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GALR3 O60755 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8659247 0.83 GLRA3 (0.61) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL47590 0.83 LMNA (0.55) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL8495448 0.82 ALOX5 (0.65) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL4448135 0.80 LMNA (0.56) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL227202 0.80 GLRA3 (0.63) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL47718 0.80 SMN1; SMN2 (0.59) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL16350239 0.80 LMNA (0.46) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL6917718 0.79 LMNA (0.51) LMNARECQLCA2CA1SMN1; SMN2
SCHEMBL4257166 0.78 LMNA (0.59) LMNARECQLCA2CA1SMN1; SMN2
Hydrochloric Acid SCHEMBL1943524 0.78 GLRA3 (0.61) LMNARECQLCA2CA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-8093427-B2 Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid NATIONAL TSING HUA UNIVERSITY (TW) 2012-01-10 US disclosed
US-20110306668-A1 CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID NATIONAL TSING HUA UNIVERSITY (TW) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731967-B2 Inhibitors of TRIM33 and methods of use TRIM33, TRIM28, TRIM4 LMNA 1670/4885RECQL 1276/4885CA2 4633/4885
US-20110306668-A1 CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID CYP4F2, ACR, CYP4F3 LMNA 1898/4885RECQL 1351/4885CA2 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.